Front-Line Combo Found Superior for Advanced RCC

Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC), according to study findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany.11/08/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news